Value
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 4.5 |
| P/S | 3.4 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 5.7 |
| PEG | 4.8 |
| Analyst target | 5.0 |
- ▸Forward P/E: 22.6x
- ▸PEG: 1.70
VRTX · Why this verdict
Why Vertex Pharmaceuticals Incorpor (VRTX) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Vertex Pharmaceuticals is a wide-moat biopharmaceutical company with a 36% net margin, compounder quality designation, strong 7.7 momentum score, and a 3-quarter earnings beat streak, trading at $450.46 with a suggested entry pullback target of $437.10 — offering a balanced risk-reward for accumulation on weakness despite concentration in cystic fibrosis medicines.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Vertex holds a wide economic moat designation with 36% net margins, a Piotroski F-Score of 8/9, and a quality score of 8.4 — among the highest in the healthcare sector — reflecting the near-monopoly position in cystic fibrosis treatments where the company's medicines address the underlying genetic cause rather than just symptoms. Quality breakdown | Net margins should remain above 30% and the quality score should stay above 8.0 over the next 12 months, confirming the moat is structural and not eroding due to competitive entry or pricing pressure. | →Stable |
| Counter100% of CF medicine revenue is concentrated in a single therapeutic area; a competitor approval or a failed label expansion into non-CF diseases would structurally reduce the addressable market and compress the premium valuation. | ||
With an RSI of 58, bullish MACD, rising OBV, and the stock trading above its 200-day moving average, Vertex is in a momentum continuation setup — all three major trend indicators are aligned positively, which is rare among large-cap biotechs. Momentum breakdown | The stock should remain above the 200-day moving average and maintain an RSI above 45 over the next 6 months, confirming the uptrend remains intact rather than rolling over. | ↑Improving |
| CounterThe stock is trading near Bollinger Band support (low score of 1.0 on Bollinger) and support/resistance (score 1.0), suggesting the technical picture is more fragile than the headline momentum score implies. | ||
Vertex has beaten earnings in 3 of the last 4 quarters, with an average surprise of 3.18% and a recent beat of 3.81% in Q1 2026 at $4.47 versus $4.31 estimated — steady execution above a consensus that is increasingly confident in the CF franchise. Earnings | Earnings per share should continue to beat consensus estimates in at least 3 of the next 4 quarters, and the analyst consensus target of $493.82 should be reached or exceeded within 12 months. | →Stable |
| CounterThe Q1 2026 miss of -2.3% at $5.03 versus $5.15 estimated shows the earnings trajectory is not perfectly linear, and any miss in a quarter where analysts have set high expectations could trigger an outsized negative reaction at this valuation. | ||
Analysts set a consensus price target of $493.82 — representing 9.6% upside from the current $450.46 — with a strong average analyst rating and LLM news sentiment of +0.47, suggesting the investment community broadly agrees on the near-term trajectory. Sentiment breakdown | The analyst consensus price target should rise above $520 within 12 months as pipeline programs beyond CF progress, expanding the multiple and the target. | →Stable |
| CounterAt 22% analyst upside and a forward P/E of 21x, Vertex is priced for consistent execution with little margin for safety if the next pipeline program fails in clinical development or faces a pricing challenge from payers. | ||
Vertex holds a wide economic moat designation with 36% net margins, a Piotroski F-Score of 8/9, and a quality score of 8.4 — among the highest in the healthcare sector — reflecting the near-monopoly position in cystic fibrosis treatments where the company's medicines address the underlying genetic cause rather than just symptoms.
→StableQuality breakdown
- Expectation
- Net margins should remain above 30% and the quality score should stay above 8.0 over the next 12 months, confirming the moat is structural and not eroding due to competitive entry or pricing pressure.
Counter100% of CF medicine revenue is concentrated in a single therapeutic area; a competitor approval or a failed label expansion into non-CF diseases would structurally reduce the addressable market and compress the premium valuation.
With an RSI of 58, bullish MACD, rising OBV, and the stock trading above its 200-day moving average, Vertex is in a momentum continuation setup — all three major trend indicators are aligned positively, which is rare among large-cap biotechs.
↑ImprovingMomentum breakdown
- Expectation
- The stock should remain above the 200-day moving average and maintain an RSI above 45 over the next 6 months, confirming the uptrend remains intact rather than rolling over.
CounterThe stock is trading near Bollinger Band support (low score of 1.0 on Bollinger) and support/resistance (score 1.0), suggesting the technical picture is more fragile than the headline momentum score implies.
Vertex has beaten earnings in 3 of the last 4 quarters, with an average surprise of 3.18% and a recent beat of 3.81% in Q1 2026 at $4.47 versus $4.31 estimated — steady execution above a consensus that is increasingly confident in the CF franchise.
→StableEarnings
- Expectation
- Earnings per share should continue to beat consensus estimates in at least 3 of the next 4 quarters, and the analyst consensus target of $493.82 should be reached or exceeded within 12 months.
CounterThe Q1 2026 miss of -2.3% at $5.03 versus $5.15 estimated shows the earnings trajectory is not perfectly linear, and any miss in a quarter where analysts have set high expectations could trigger an outsized negative reaction at this valuation.
Analysts set a consensus price target of $493.82 — representing 9.6% upside from the current $450.46 — with a strong average analyst rating and LLM news sentiment of +0.47, suggesting the investment community broadly agrees on the near-term trajectory.
→StableSentiment breakdown
- Expectation
- The analyst consensus price target should rise above $520 within 12 months as pipeline programs beyond CF progress, expanding the multiple and the target.
CounterAt 22% analyst upside and a forward P/E of 21x, Vertex is priced for consistent execution with little margin for safety if the next pipeline program fails in clinical development or faces a pricing challenge from payers.
Per-dimension breakdown
Quality
8.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 8.1 |
| ROA | 8.1 |
| Gross margin | 6.9 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 10.0 |
| FCF quality | 4.9 |
| Moat | 8.4 |
| Piotroski F | 8.9 |
- ▸Strong margins: 36%
- ▸Earnings quality warning: 64% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
7.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.4 |
| EPS growth | 10.0 |
Momentum
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.0 |
| OBV | 2.0 |
| MA position | 6.0 |
| Volume | 0.5 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.8 |
| Analyst rating | 7.5 |
| Price target | 7.1 |
- ▸LLM news sentiment: +0.35 (n=7)
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Insider selling (low materiality) — $8,890,220 (0.007% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.4 |
| quality rank | 8.7 |
| growth rank | 4.4 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.4 |
| support resistance | 7.4 |
| 52w position | 8.1 |
Risk (lower is worse)
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.9 |
| days to cover | 8.1 |
| volatility | 4.4 |
| put call | 5.3 |
| implied vol | 5.7 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 9.6 |
| news risk | 5.0 |
- ▸Above max pain $410
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 4.1 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
- ▸Earnings in 12 days
How the verdict was assembled
Engine trigger
Wide-moat business. Accumulate on weakness.
Engine technical detail
verdict_path:
L4:PATH_E_WIDE_MOAT|ENTRY_STICKY:WITHIN_BANDPassed (4)
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:2.8<4.5
- ASYMMETRY:0.5<1.5@spot
Warning (2)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:12d<=14d (soft)
Reward-to-Risk
0.54
Upside
+3.5%
Downside
6.5%
Sizing output
STARTER
SetupRange Bound — RSI 43 mid-range, Bollinger mid-band
EdgeTemporary headwind — High quality (8.4) with weak momentum (2.8)
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The STRONG_BUY_WAIT verdict reflects the MOMENTUM gate's 2.8<4.5 outcome against Quality at 8.4 and asymmetric R:R of 0.54.
The strongest dimensions are Quality at 8.4, Insider at 7.3, and Technical at 7.3; the weakest are Momentum at 2.8, Value at 4.2, and Peer rank at 5.6. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 0.54 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Cf Franchise
Trip ifNet margin falls below 28%, more than 8 percentage points below the current 36%, for 2 consecutive quarters.
- P2Momentum Continuation Above 200ma
Trip ifStock price falls below $413, more than 8% below the current $450.46, and the 200-day moving average is breached to the downside.
- P3Earnings Beat Trajectory
Trip ifEPS surprise falls below 0% in at least 3 of the next 4 quarters.
- P4Analyst Price Target Upside
Trip ifAnalyst consensus price target falls below $440, more than 2% below the current stock price, indicating analysts are cutting targets below current trading levels.